ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives

Clin Lung Cancer. 2019 Nov;20(6):e593-e596. doi: 10.1016/j.cllc.2019.06.007. Epub 2019 Jun 13.
No abstract available

Keywords: Cabozantinib; Crizotinib; G2032R ROS1 mutation; ROS1 inhibitors; Secondary resistance mutation.

Publication types

  • Case Reports

MeSH terms

  • Anilides / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Crizotinib / therapeutic use*
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Staging
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / genetics
  • Pyridines / therapeutic use*
  • Treatment Failure

Substances

  • Anilides
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Pyridines
  • cabozantinib
  • Crizotinib
  • Protein-Tyrosine Kinases
  • ROS1 protein, human